Quick Facts: Largactil IM

• Psychotic Manifestations: Management of symptoms associated with psychotic disorders, including schizophrenia and the manic phase of bipolar illness.
• Nausea and Vomiting: Used to help control persistent nausea and vomiting.
• Hiccups: Provides relief for intractable hiccups that do not respond to other measures.
• Other Uses: Employed as an adjunct in treating tetanus and for the management of acute intermittent porphyria.

Largactil IM (chlorpromazine) is a medication utilized in the clinical setting to manage a range of conditions. It is indicated for the management of the manifestations of psychotic disorders, such as schizophrenia, and is employed to help control the manifestations of the manic type of manic-depressive illness. Additionally, this medication may be used to assist in the control of persistent and severe nausea and vomiting.

Its therapeutic domains also include providing relief for intractable hiccups and managing the symptoms of acute intermittent porphyria. The injection formulation may also be administered to help relieve restlessness and apprehension before surgical procedures. The use of Largactil IM is determined by a qualified healthcare professional based on the specific condition and patient needs.

Regulatory References

1. NIH MedlinePlus guidance

Absolute Contraindications

The medicine is strictly contraindicated in specific populations as defined by regulatory labeling. Individuals who must not use Largactil IM include those with a known hypersensitivity to any phenothiazine drug, patients in comatose states, or those exhibiting severe Central Nervous System (CNS) depression. Absolute prohibition also applies to patients with bone marrow depression or Phaeochromocytoma. Furthermore, official warnings mandate that this medicine is contraindicated for use in elderly patients with dementia-related psychosis.

Age-Group Eligibility

The medicine is approved for use in adults and in children aged 6 months and older for selected conditions. Use is generally not recommended for infants younger than 6 months of age due to insufficient safety and efficacy data documented in regulatory materials.

Conditional and Restricted Use

Largactil IM requires caution or is restricted in several clinical contexts. Use should be approached cautiously in patients with severe hepatic or renal impairment and those with cardiovascular disease. For pregnant individuals, use is not recommended unless the treating physician determines that the potential benefits clearly outweigh the possible hazards. The drug is also excreted in breast milk, leading some authorities to not recommend its use while breastfeeding.

Largactil IM’s interaction profile is categorized by regulatory bodies into several domains based on the potential outcome of co-administration. The structure addresses severe prohibitions, pharmacokinetic changes, and requirements for administration timing.

Interaction Type	Interacting Substance/Class	Formal Regulatory Outcome
Pharmacodynamic Risk	CNS Depressants (e.g., Opioids, Barbiturates)	Prolongs and intensifies effects, including profound sedation and respiratory risk.
	Adrenaline (Epinephrine)	Use is prohibited to treat hypotension, as the drug may reverse Adrenaline’s pressor action.
	QT-Prolonging Drugs (e.g., Sotalol, Citalopram, Escitalopram)	Combination is contraindicated due to risk of serious ventricular arrhythmias (torsade de pointes).
Pharmacokinetic / Exposure	CYP2D6 Inhibitors (e.g., Paroxetine)	Reduces Chlorpromazine clearance, increasing its systemic exposure.
	Antacids / GI Agents	Impairs gastrointestinal absorption of Chlorpromazine.

Timing and Substance Restrictions:

To prevent reduced absorption, antacids and topical gastrointestinal agents must be administered at least 2 hours apart from Chlorpromazine. Consumption of alcohol must be avoided throughout treatment due to the increased risk of combined sedative and hypotensive effects. Caution is noted in patients with hepatic impairment due to the extensive hepatic metabolism of Chlorpromazine, which may affect clearance and exposure.

Largactil IM (chlorpromazine) is a broad-spectrum agent that exerts its effects by modulating several key neurochemical pathways. Its mechanism involves blocking specific receptors, which modulates or reduces excessive signaling in physiological processes. The mechanism of action involves primary D2 receptor-mediated effects and secondary broad receptor-mediated effects.

Dopamine and Serotonin Receptor Blockade: Core Mechanism

This domain covers the drug's essential action as an antagonist, primarily at dopamine D2 receptors and, secondarily, serotonin 5-HT2A receptors in the brain. By interfering with these primary molecular steps, the drug results in a reduction of excessive mediator activity and influences the dynamics of overactive signaling within neural circuits.

Modulating Autonomic and Histamine Systems: Immediate Physiological Effects

This mechanistic domain involves the drug's action on other key receptors, notably histamine H1 and alpha1-adrenergic receptors. The blockade of these systems initiates or suppresses signaling sequences that lead to immediate downstream effects, modulating CNS activity, including H1 receptor-mediated pathway depression and causing predictable physiological adjustments that influence the immediate physiological consequences of the drug's action.

The administration of Largactil IM (Chlorpromazine Injection) follows specific protocols focused on route, dose, and administration technique. This formulation is primarily administered via deep Intramuscular (IM) injection into a large muscle mass, such as the upper outer quadrant of the buttock. The Intravenous (IV) route is restricted for highly specific indications, such as intractable hiccups, and requires careful dilution before slow administration. Subcutaneous administration is not advised.

For prompt control of severe symptoms in adults, the typical initial dose is 25 mg and may be followed by an additional 25–50 mg after one hour, then repeated every four to six hours until the patient is stabilized. The IM regimen is designated for short-term, acute intervention and should be substituted with the oral form as soon as the patient is able and cooperative.

Standard protocols include specific procedural steps, such as ensuring the patient remains lying down (supine) for at least 30 minutes following the injection. Dosage adjustments are mandatory for certain populations; for older adults, doses are generally lower and increased more gradually. Similarly, pediatric patients (6 months to 12 years) receive weight-based dosing, with strict maximum daily IM limits. The solution may be diluted with saline or 2% procaine if local irritation occurs at the injection site.

Research Evidence for Acute Behavioral Management

Largactil IM was studied for applied in research contexts involving fluctuating or unstable symptoms related to severe excitement, agitation, or aggression. The evidence in this area largely comes from older, short-term Randomized Controlled Trials (RCTs) and subsequent Systematic Reviews that examined how researchers monitored outcomes related to the management of these acute episodes. Findings describe patterns observed in the studies over short time intervals, often hours or days, primarily assessing overall changes in the patient’s global condition. However, independent Systematic Reviews have frequently described the available evidence as limited and heterogeneous. Comparative evidence is lacking in recently conducted high-quality trials that would compare the injection to current standard treatments for acute agitation.

---

Evidence for Controlling Severe Nausea and Vomiting

The use of chlorpromazine injection was studied for conditions associated with acute or disruptive episodes such as severe or persistent nausea and vomiting. The evidence was evaluated in various clinical studies and is primarily supported by decades of observational settings evaluating daily-life functioning and clinical experience described in official regulatory materials. Findings describe patterns observed in the studies related to the control or cessation of vomiting, which evidence contributes to understanding symptom patterns. What remains uncertain is the precise role of the injection form against newer classes of antiemetic drugs, as comparative evidence is lacking from recent, specific, randomized, placebo-controlled trials.

---

Research Base for Persistent Hiccuping (Intractable Singultus)

Largactil IM was studied for the specific and rare condition of intractable hiccups. The research base appears to be limited, with evidence primarily derived from older clinical reports, case studies, and historical data. Evidence for the use is associated with patterns observed in the studies over time and extensive clinical experience, rather than a broad base of modern, controlled trials. Systematic reviews note that high-quality, randomized trials specific to chlorpromazine are scarce. The sample sizes were modest in the available research, which is a common limitation frame for rare conditions.

Key Studies & References

1. Chlorpromazine Hydrochloride Injection, USP (FDA-equivalent Prescribing Information)

Common questions about Largactil IM (FAQ)

Q: What is the main difference between the Largactil IM injection and the oral tablets?

Official information indicates that there is a difference in how the medicine is processed by the body. Following intramuscular (IM) injection, the concentration of the medicine in the bloodstream is typically much higher than what is achieved after taking the oral tablets.

Q: How does the medicine release into the body from the intramuscular injection site?

According to regulatory information, after a deep intramuscular injection, the medicine is absorbed slowly into the systemic circulation. The highest concentration of the medicine in the blood usually occurs between 6 to 24 hours after the injection.

Q: How quickly does the therapeutic effect of a Largactil IM injection start?

Regulatory documents state that the onset of action for the intramuscular injection is typically within 15 to 20 minutes.

Q: What is the expected duration of effect for a single dose of Largactil IM?

The primary duration of action for a single dose is generally 8 to 12 hours. However, some residual effects of the medicine may be observed for up to 3 weeks.

Q: Is it common to experience pain or soreness at the injection site after receiving Largactil IM?

Local pain may occur at the injection site following the intramuscular injection. Regulatory information also notes that nodule formation, which is a small lump or bump, may occasionally occur.

Q: Can the injection cause a temporary bump or nodule under the skin?

Yes, official product information includes nodule formation as a possible local reaction that may occur at the intramuscular injection site.

Q: Do patients need to take other oral medications when they first start Largactil IM?

Regulatory guidelines emphasize the importance of informing a healthcare professional about all current prescription and over-the-counter medications, including those for anxiety or depression. Combining Largactil IM with certain medicines, especially those that cause sleepiness, can increase sedative effects.

Q: Is weight gain a common side effect associated with Largactil IM?

Weight gain is listed in regulatory documents as a potential side effect of the medicine, and some sources classify it as common. Regulatory labels suggest that body weight is typically monitored during treatment.

Q: What kind of changes to sleep patterns can be expected with Largactil IM?

Side effects include sedation and somnolence (drowsiness) as very common effects. Rarely, insomnia (trouble sleeping) has also been reported.

Q: What are the early warning signs of uncontrolled movements (dyskinesia) that a patient should know about?

Symptoms of movement disorders like dyskinesia may include muscle spasms, especially in the face or neck, difficulty swallowing, or rapid, uncontrollable, worm-like movements of the tongue. This information is noted in regulatory materials as part of the safety profile.

Q: What is Neuroleptic Malignant Syndrome (NMS), and how is it related to Largactil IM?

NMS is a rare, but potentially life-threatening reaction associated with antipsychotic drugs, including Largactil IM. Official safety information describes it as being characterized by a severe muscle rigidity, very high fever, altered mental status, and unstable blood pressure or heart rate.

Q: Why does Largactil IM sometimes lead to dry mouth or constipation?

Largactil is classified as a low-potency first-generation antipsychotic, which has anticholinergic blocking activity. This activity is what commonly results in certain non-neurologic side effects such as dry mouth and constipation.

Q: Is a stuffy nose or nasal congestion a common side effect of Largactil?

Yes, regulatory documents list nasal congestion or stuffiness as a common side effect.

Q: Can Largactil IM affect eye sight, such as causing blurred vision?

Blurred vision is a listed common side effect. It is primarily related to the medicine's effect on certain receptors in the body. Long-term exposure to the medicine may also cause corneal deposits.

Q: Are there certain types of over-the-counter medicines or supplements that should be avoided with Largactil IM?

Caution is advised with all over-the-counter (OTC) medications and supplements. Specifically, OTC medicines that cause sleepiness (like some cold or allergy products) and certain herbal products, such as St. John’s Wort, are items that should be brought to the attention of a healthcare provider.

Q: Can Largactil IM affect how other medicines for depression or anxiety work?

Co-administration with medicines for depression or anxiety that have sedative properties can increase drowsiness. Additionally, official documents indicate that some medicines, including certain antidepressants, may increase the risk of serious heart rhythm changes when combined with Largactil.

Q: How does Largactil IM make a person's skin more sensitive to sunlight?

The medicine is known in official documents to cause photosensitivity, which is an increased or abnormal sensitivity to light. This can result in severe sunburn if the skin is exposed to strong sunlight.

Q: What precautions related to sun exposure should be followed when taking Largactil?

Regulatory warnings note the importance of avoiding strong sunlight exposure. Official precautions typically include wearing suitable protective clothing, such as a hat, and applying a broad-spectrum sunscreen with an SPF of 15 or higher.

Q: Does Largactil IM affect the body’s ability to regulate its temperature in hot or cold weather?

Phenothiazines, including Largactil, can interfere with the body’s natural temperature regulation. This means there is a risk of severe hypothermia in cold conditions and heat stroke in hot weather, as stated in regulatory documents.

Q: Can a person with a history of seizures or epilepsy use Largactil IM?

Regulatory information advises that Largactil should generally not be used in patients with epilepsy. The drug is also rarely known to cause seizures or convulsions.

Q: Does Largactil IM interact with medication for high blood pressure?

Caution is advised when Largactil is used alongside other medicines that can cause postural hypotension (a drop in blood pressure when changing position). In such cases, managing the dosage of both medicines may be necessary.

Q: Is it true that Largactil IM is only given to patients with very severe or resistant mental health conditions?

No, this is an oversimplification. While Largactil IM is used for rapid stabilization during acute, severe behavioral disruption, it is also specifically indicated for other medical uses, such as controlling severe nausea, vomiting, and intractable hiccups, according to official labels.

Q: What are the possible effects of Largactil IM on blood sugar levels or diabetes management?

Common metabolic side effects listed in official information include impaired glucose tolerance and hyperglycemia (high blood sugar).

Q: Can taking Largactil IM for a long time lead to changes in sex drive or sexual function?

Side effects reported in official documents include hyperprolactinaemia (elevated prolactin levels), decreased sexual ability, and changes in libido (sex drive).

Q: What is the difference in side effect profiles between first-generation (like Largactil) and second-generation antipsychotics?

Largactil is a low-potency first-generation antipsychotic. Regulatory-derived literature indicates that it typically causes more anticholinergic side effects (e.g., dry mouth, blurred vision) and sedation, but less muscle stiffness or rigidity compared to high-potency first-generation drugs.

Q: Is it possible to become psychologically dependent or 'addicted' to Largactil IM?

Regulatory documents state that Largactil is not known to cause psychic dependence, tolerance, or addiction. However, physical withdrawal symptoms can occur if long-term therapy is stopped abruptly.

Q: What should be monitored by healthcare professionals while a person is on Largactil IM?

Official guidelines recommend that monitoring should include checking body weight and taking blood tests before and during treatment. This monitoring also includes watching for changes in heart rhythm and signs of serious adverse effects like Neuroleptic Malignant Syndrome (NMS).

Q: Can Largactil IM affect the results of blood tests or other lab work?

Yes. The medicine is associated with a risk of severe blood dyscrasias (a blood cell disorder like Agranulocytosis), elevated muscle enzymes, and signs of liver issues (like jaundice) that would be detected by lab tests, according to official safety information.

Q: Why is it important not to stop taking Largactil IM suddenly?

Abrupt cessation of the medicine, especially after high-dose or long-term use, can cause physical withdrawal symptoms. These symptoms may include nausea, vomiting, dizziness, and movement disorders. Regulatory information indicates that gradual withdrawal is typically recommended.

How to Store and Dispose of Largactil (Chlorpromazine Hydrochloride) Injection

The storage and disposal instructions for Largactil IM are defined by regulatory labeling to ensure product integrity and safety.

Storage Requirements

Ampoules must be stored at Controlled Room Temperature, which is defined as 20 C to 25 C (68 F to 77 F). The injection must be protected from light and freezing must be avoided. The solution is not suitable for storage after the ampoule is opened and must be used immediately.

Handling and Safety

The medicine must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Largactil IM must not be discharged to sewer systems or be allowed to contaminate water. Disposal of the contents and container must be done at a hazardous or special waste collection point in accordance with local regulations, and guidance should be sought from a pharmacist for leftover medicine.